MS PATIENT VOICES CALL TO ACTION
We need your voice to help expand patient access to medical cannabis in Mississippi!
Contact the Public Health & Welfare Committee TODAY and ask them to support SB 2745 & SB 2748.
✅ SB 2745: Adds anxiety & sleep disorders as qualifying conditions under the MS Medical Cannabis Act. Patients report significant improvement in managing these conditions with medical cannabis!
✅ SB 2748: Ensures patients have access to clean, effective medicine without unnecessary restrictions.
Hob Bryan, Chairman hbryan@senate.ms.gov
David Parker dparker@senate.ms.gov
Juan Barnett jbarnett@senate.ms.gov
Kevin Blackwell kblackwell@senate.ms.gov
David Blount dblount@senate.ms.gov
Dennis DeBar, Jr. ddebar@senate.ms.gov
Josh Harkins jharkins@senate.ms.gov
Rod Hickman rhickman@senate.ms.gov
Angela Burks Hill ahill@senate.ms.gov
Briggs Hopson bhopson@senate.ms.gov
Chris Johnson chjohnson@senate.ms.gov
Chad McMahan cmcmahan@senate.ms.gov
Rita Potts Parks rparks@senate.ms.gov
John A. Polk jpolk@senate.ms.gov
Jeff Tate jtate@senate.ms.gov
Angela Turner-Ford aturner@senate.ms.gov
Brice Wiggins bwiggins@senate.ms.gov
Feel free to copy and paste the email below, just add your information to the bottom
Dear Sir or Madam,
Mississippi Patient Voices urges you to bring forth the following bills:
SB 2745 to include “anxiety disorders” and “sleep disorders” under the definition of “debilitating condition” within the MS Medical Cannabis Act.
SB2748 “to designate one unit of MMCEU as one gram of total THC in a cannabis concentrate or one gram of total THC in an infused product”
Mississippi Patient Voices is a political action committee created for patients by patients. We have collected stories from patients and would-be patients from around the state. Patients report significant improvement in the management of their anxiety and sleep quality. Would-be patients report the need for treatment of anxiety and sleep disorders.
Both of these bills are patient-needs centered and serve the best interests of the overall health of Mississippians. Anxiety disorders, including generalized anxiety disorder (GAD), panic disorder, social anxiety disorder, and post-traumatic stress disorder (PTSD), affect a significant portion of Mississippi’s population, contributing to public health challenges, diminished workforce productivity, and increased healthcare costs.
Conventional pharmaceutical treatments for anxiety, such as benzodiazepines and SSRIs, often have significant side effects, dependency risks, and long-term inefficacy, leaving many patients without sufficient treatment options. By expanding Mississippi’s medical cannabis program to include anxiety disorders, the state can provide a safer, potentially more effective alternative to traditional medications and offer the safest pathway to the use of this valuable alternative.
SB2748 ensures patients can get equivalent doses and allotments of non-smokeable forms to adequately treat their condition, thus preventing them from having to use primarily smokeable/inhaled forms to treat their condition.
Respectfully,
[Your Name]